文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

抗菌包膜预防心脏植入式电子设备感染

Antibacterial Envelope to Prevent Cardiac Implantable Device Infection.
PubMed 文献 · N Engl J Med · 2019-03-17

这项随机对照试验评估可吸收抗菌洗脱包膜能否降低心脏植入式电子设备(CIED)植入相关感染。6983例患者按1:1随机分为包膜组(3495例)和对照组(3488例),主要终点为12个月内导致系统拔除或修正、长期抗生素治疗伴感染复发或死亡的感染。包膜组主要终点12个月Kaplan-Meier估计事件率为0.7%,对照组为1.2%(HR 0.60,95%CI 0.36-0.98,P=0.04),安全性终点两组无显著差异。

要点

  • 抗菌包膜组主要终点12个月事件率0.7% vs 对照组1.2%(HR 0.60,95%CI 0.36-0.98,P=0.04)。
  • 安全性终点12个月事件率包膜组6.0% vs 对照组6.9%(HR 0.87,95%CI 0.72-1.06,非劣效性P<0.001)。
  • 全随访期主要CIED相关感染包膜组32例 vs 对照组51例(HR 0.63,95%CI 0.40-0.98)。

核心结论

  • 在标准感染预防策略基础上辅助使用抗菌包膜可显著降低主要CIED感染发生率,且不增加并发症发生率。

研究设计与样本

  • 随机对照临床试验,纳入接受CIED囊袋修正、脉冲发生器更换、系统升级或初始心脏再同步治疗除颤器植入的患者,按1:1随机分配接受或不接受抗菌包膜,所有患者均采用标准感染预防策略。
  • 共6983例患者随机分组:包膜组3495例,对照组3488例;平均随访20.7±8.5个月。

主要发现

  • 主要终点(12个月内导致系统拔除或修正、长期抗生素治疗伴感染复发或死亡的感染)包膜组25例 vs 对照组42例,12个月Kaplan-Meier估计事件率分别为0.7%和1.2%(HR 0.60,95%CI 0.36-0.98,P=0.04)。
  • 安全性终点(12个月内操作相关或系统相关并发症)包膜组201例 vs 对照组236例,12个月Kaplan-Meier估计事件率分别为6.0%和6.9%(HR 0.87,95%CI 0.72-1.06,非劣效性P<0.001)。
  • 全随访期主要CIED相关感染包膜组32例 vs 对照组51例(HR 0.63,95%CI 0.40-0.98)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Infections after placement of cardiac implantable electronic devices (CIEDs) are associated with substantial morbidity and mortality. There is limited evidence on prophylactic strategies, other than the use of preoperative antibiotics, to prevent such infections. METHODS: We conducted a randomized, controlled clinical trial to assess the safety and efficacy of an absorbable, antibiotic-eluting envelope in reducing the incidence of infection associated with CIED implantations. Patients who were undergoing a CIED pocket revision, generator replacement, or system upgrade or an initial implantation of a cardiac resynchronization therapy defibrillator were randomly assigned, in a 1:1 ratio, to receive the envelope or not. Standard-of-care strategies to prevent infection were used in all patients. The primary end point was infection resulting in system extraction or revision, long-term antibiotic therapy with infection recurrence, or death, within 12 months after the CIED implantation procedure. The secondary end point for safety was procedure-related or system-related complications within 12 months. RESULTS: A total of 6983 patients underwent randomization: 3495 to the envelope group and 3488 to the control group. The primary end point occurred in 25 patients in the envelope group and 42 patients in the control group (12-month Kaplan-Meier estimated event rate, 0.7% and 1.2%, respectively; hazard ratio, 0.60; 95% confidence interval [CI], 0.36 to 0.98; P = 0.04). The safety end point occurred in 201 patients in the envelope group and 236 patients in the control group (12-month Kaplan-Meier estimated event rate, 6.0% and 6.9%, respectively; hazard ratio, 0.87; 95% CI, 0.72 to 1.06; P<0.001 for noninferiority). The mean (±SD) duration of follow-up was 20.7±8.5 months. Major CIED-related infections through the entire follow-up period occurred in 32 patients in the envelope group and 51 patients in the control group (hazard ratio, 0.63; 95% CI, 0.40 to 0.98). CONCLUSIONS: Adjunctive use of an antibacterial envelope resulted in a significantly lower incidence of major CIED infections than standard-of-care infection-prevention strategies alone, without a higher incidence of complications. (Funded by Medtronic; WRAP-IT ClinicalTrials.gov number, NCT02277990.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Tarakji KG, Mittal S, Kennergren C, et al. Antibacterial Envelope to Prevent Cardiac Implantable Device Infection. N Engl J Med. 2019. PMID: 30883056. doi:10.1056/NEJMoa1901111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。